6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2018

Commission File Number: 001-32001 

Aptose Biosciences Inc.
(Translation of registrant's name into English)

251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): 

On September 25, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated September 25, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aptose Biosciences Inc.
	(Registrant)
Date: September 25, 2018	/s/ Gregory K. Chow
	Gregory K. Chow
	Senior Vice President and Chief Financial Officer

EX-99.1

EXHIBIT 99.1

Aptose to Present at Upcoming Investor Conferences in October 2018

SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the following upcoming conferences:

·	2018 Cantor Fitzgerald Global Healthcare Conference
	Date:	Tuesday, October 2, 2018
	Time:	8:00 a.m. EDT
	Format:	Company Presentation
	Location:	Intercontinental New York Barclay Hotel, New York City
	Live webcast:	Cantor Fitzgerald Conference Webcast Link
·	Leerink Partners Roundtable Series: Rare Disease & Oncology
	Date:	Wednesday, October 3, 2018
	Time:	2:00 p.m. EDT
	Format:	Fireside Chat
	Location:	Lotte New York Palace Hotel, New York City
	Live webcast:	Leerink Partners Conference Webcast Link
·	18th Annual Biotech in Europe Forum
	Date:	Friday, October 5, 2018
	Location:	Centre Congress, Basel, Switzerland
		9:45 a.m. CEST – Company Presentation
		12:10 p.m. CEST – Oncology II – Advanced Therapeutics Panel

The live webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Greg Chow, CFO 647-479-9828 gchow@aptose.com
SMP Communications Susan Pietropaolo 201-923-2049 susan@smpcommunications.com	LifeSci Advisors Michael Wood Managing Director 646-597-6983 mwood@lifesciadvisors.com